Navigation Links
KV Pharmaceutical Suspends Product Manufacturing, Shipping
Date:1/26/2009

"could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, revenues, expenditures, resumption of distribution of tablet-form products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the introduction and impact of competitive products and pricing, including as a result of so- called authorized-generic drugs; (5) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (6) reliance on key strategic alliances; (7) the availability of raw materials and/or products manufactured for the Company under contract manufacturing arrangements with third parties; (8) the regulatory environment, including regulatory agency and judicial actions and changes in applicable law or regulations; (9) fluctuations in revenues; (10) the difficulty of
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... better understanding of drug interactions, which are a major ... two or more medications are taken at the same ... the other. Similarly, one drug may magnify the ... major cause of illness and hospitalization. However, there ... drug studies in humans. Limits come in part ...
(Date:4/24/2014)... lenses coated with an antimicrobial peptide could help to lower ... Optometry and Vision Science , official journal ... journal is published by Lippincott Williams & Wilkins , ... in animals and now humans support the biocompatibility and safety ... the new research by Debarun Dutta, B.Optom, of The University ...
(Date:4/24/2014)... April 28, the Center for BrainHealth will bring ... most pressing brain-related challenges at its inaugural Brain ... and Regeneration." Featured speakers will include Dr. Sandra ... Center for BrainHealth, U.S. Senator Chuck Grassley (R-IA), ... Deputy Assistant Secretary for Policy and Early Learning, ...
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2
... NEW YORK, May 12 portionpals(R), an innovative,weight-loss tool ... million sales mark,this past Saturday, May 10th, in less ... the "diet" alternative among consumers,looking for a healthy way ... is,gaining market share in a multi-billion dollar industry with ...
... serious, but genetics could bring screening test or treatment , , ... COMT, already known for its role in schizophrenia, also plays ... preeclampsia, a new study finds. , Although the current study ... the findings could be used as a test to identify ...
... MEDX ) announced today its financial results for the quarter ... or $1.19 per share, from Medarex,s,sale of 2.5 million shares ... the quarter ended March 31, 2008, was $103.3 million, or,$0.81 ... million, or $0.88,per share for the same period in 2007. ...
... DUBLIN, Ohio, May 12 On May 30, 2008, ... Chicago, New York,Philadelphia, Cleveland, Madison, Atlanta, Seattle, Dearborn, and ... Abigail Alliance, A Right,To Live, and the Sarcoma Foundation ... out and attend a protest., 1 in 6 ...
... MedCath Corporation,(Nasdaq: MDTH ), a health ... predominantly the diagnosis and treatment of cardiovascular,disease, today ... currently Interim Chief Financial Officer, has been named,Senior ... his new role, Art will continue to oversee ...
... YORK, May 12 InfuSystem Holdings, Inc.,(OTC Bulletin ... infusion pumps and associated clinical services, today announced,financial ... first quarter of,2008., Mr. Steve Watkins, chief ... of our first full quarter of operations as ...
Cached Medicine News:Health News:Diet Industry Newcomer Hits the 1 Million Unit Mark 2Health News:Gene May Be Key to Pregnancy Complication 2Health News:Gene May Be Key to Pregnancy Complication 3Health News:Medarex Announces 2008 First Quarter Financial Results 2Health News:Medarex Announces 2008 First Quarter Financial Results 3Health News:Medarex Announces 2008 First Quarter Financial Results 4Health News:Medarex Announces 2008 First Quarter Financial Results 5Health News:Medarex Announces 2008 First Quarter Financial Results 6Health News:Medarex Announces 2008 First Quarter Financial Results 7Health News:Medarex Announces 2008 First Quarter Financial Results 8Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 2Health News:FDA Says, 'Wait' To Dying Men; Coast-To-Coast Prostate Cancer Demonstrations on May 30th in Protest of FDA Failure to Approve Safe, Effective Immunotherapy 3Health News:MedCath Names Parker to New Finance Post 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 15, 2014 The Cadence Fitness & Health Center ... the Medical Fitness Association, a non-profit organization assisting medically ... potential. The Cadence Fitness & Health Center is the ... second in the Chicagoland area. "The certification ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Vista 1500 integrated system will ... (integrated multisensor technology) and LOCI ... integrate analysis of electrolytes, general ... drugs, immunosuppressive drugs, plasma proteins, ...
... flexibility to floor-mounted X-ray systems. The ... the C-arm around the exam table ... angle for cardiac and general angiography. ... flat panel detector that delivers outstanding ...
... In-office. Information. In real time. The FemExam pH ... elevated vaginal fluid pH (pH >= 4.7) and ... is easy to use and delivers accurate results ... a swab containing unprocessed vaginal fluid across each ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
Medicine Products: